Nicholas J. Robert, MD

The study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.

Nicholas J. Robert, MD, discusses a study of the social determinants of a patient’s health related to the use of genomic testing in women with breast cancer.

Nicholas J. Roberts, discusses real-world research around the adoption of germline testing for breast cancer, and the testing gap in certain racial groups.

Today, we are in the heyday of biomarker discovery, utilization, and translation to clinical practice.

Nicholas J. Robert, MD, discusses the poster on the MYLUNG Consortium that he presented at the 2022 American Society of Clinical Oncology Annual Meeting.

Nicholas J. Robert, MD, discusses the main findings from the MYLUNG Consortium.